TRACON Pharmaceuticals Announces Appointment of Brian Daniels, M.D., to Scientific Advisory Board
“Brian brings extensive experience in the immune oncology area to our SAB, and we are thrilled to add his expertise to our team," said Charles P. Theuer, M.D., Ph.D., President and CEO of TRACON. "He was instrumental in the clinical development and commercialization of several immune oncology assets at BMS, and his experience should prove particularly valuable as we begin a trial of our lead antibody, TRC105, in combination with Opdivo in lung cancer."
“I look forward to working with the team at TRACON and am excited about this opportunity to contribute to the science and clinical strategy,” said Dr. Daniels.
Dr. Daniels was Senior Vice President at
Dr. Daniels earned his B.S. and M.S. from the
TRACON develops targeted therapies for cancer, ophthalmic and fibrotic diseases. The Company’s clinical-stage pipeline includes: TRC105, an endoglin antibody that is being developed for the treatment of multiple cancers; DE-122, the ophthalmic formulation of TRC105 that is being developed in wet AMD through a collaboration with
Chief Business Officer
(858) 550‐0780 ext. 236
LifeSci Advisors LLC
Source: TRACON Pharmaceuticals, Inc.